
CLAIMS

1. A compound with structure of the following formula:



or a pharmaceutically acceptable salt, ester, or solvate thereof,

wherein:

L^1 is $-NR^5-$;

L^2 is a bond;

L^3 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, -S-, -SO-, $-SO_2-$, -O-, $-NHSO_2-$, or $-NR^5-$;

L^4 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, -S-, -SO-, $-SO_2-$, -O-, $-NHSO_2-$, or $-NR^5-$;

R^1 is substituted alkyl;

R^2 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted fused ring aryl, or substituted or unsubstituted heteroaryl;

R^3 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein when R^3 is substituted heteroaryl, any substituent group of said R^3 substituted heteroaryl is selected from the group consisting of -OH, $-NH_2$, -SH, -CN, $-CF_3$, $-NO_2$, halogen, -COOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;

R^4 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and

R^5 is hydrogen, or substituted or unsubstituted alkyl.

2. The compound according to claim 1, wherein L^3 is a bond, or substituted or unsubstituted alkylene, and R^3 is substituted or unsubstituted aryl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, or substituted or unsubstituted heteroaryl.

3. The compound according to claim 1, wherein L^3 is -C(O)O-, and R^3 is substituted or unsubstituted alkyl.

4. The compound according to claim 1, wherein L^3 is $-C(O)NR^6-$, R^6 is hydrogen or alkyl, and R^3 is substituted or unsubstituted alkyl, or substituted or unsubstituted aryl.

5. The compound according to claim 2, wherein R^3 is phenyl or pyridyl.

6. The compound according to claim 1, wherein R^1 is substituted alkyl, substituted with substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

7. The compound according to claim 1, wherein R^2 is substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocycloalkyl.

8. The compound according to claim 1, wherein L^4 is a bond, and R^4 is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.

9. The compound according to claim 8, wherein R^4 is unsubstituted alkyl.

10. The compound according to any one of claims 1 to 9, wherein the compound is selected from the group consisting of:

N-benzyl-1-[(naphthalen-1-yl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

N-benzyl-1-[(naphthalen-2-yl)carbonyl]-3-(pyridin-2-yl)-1H-pyrazol-5-amine;

N-benzyl-3-(2-fluorophenyl)-1-[(thiophen-3-yl)carbonyl]-1H-pyrazol-5-amine; and

N-benzyl-3-(pyridin-2-yl)-1-[(thiophen-3-yl)carbonyl]-1H-pyrazol-5-amine.

11. The compound according to any one of claims1 to 9, wherein the compound is selected from the group consisting of:

N-benzyl-1-[(furan-2-yl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

N-benzyl-1-[(furan-2-yl)carbonyl]-3-phenyl-1H-pyrazol-5-amine;

N-benzyl-1-[(pyridin-2-yl)carbonyl]-3-(pyridin-3-yl)-1H-pyrazol-5-amine;

N-benzyl-3-(pyridin-3-yl)-1-[(pyridin-3-yl)carbonyl]-1H-pyrazol-5-amine;

N-benzyl-3-(pyridin-3-yl)-1-[(pyridin-4-yl)carbonyl]-1H-pyrazol-5-amine;

N-benzyl-3-(pyridin-3-yl)-1-[(thiophen-2-yl)carbonyl]-1H-pyrazol-5-amine;

N-benzyl-3-phenyl-1-[(pyridin-2-yl)carbonyl]-1H-pyrazol-5-amine;

N-benzyl-3-phenyl-1-[(pyridin-3-yl)carbonyl]-1H-pyrazol-5-amine;

N-benzyl-3-phenyl-1-[(pyridin-4-yl)carbonyl]-1H-pyrazol-5-amine; and

N-benzyl-3-phenyl-1-[(thiophen-2-yl)carbonyl]-1H-pyrazol-5-amine.

12. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 11, and a pharmaceutically acceptable excipient.

13. The compound according to any one of claims 1 to 11 or the pharmaceutical composition according to claim 12, for use in treatment of at least one of a thrombotic disorder and a disease or disorder comprising a blood clot thrombus.

14. The compound or composition according to claim 13, wherein said thrombotic disorder comprises one or more of acute coronary syndrome, thromboembolism, and thrombosis.

15. The compound or composition according to claim 14, wherein the thromboembolism comprises at least one of venous thromboembolism, arterial thromboembolism, and cardiogenic thromboembolism.

16. The compound or composition according to claim 15, wherein the venous thromboembolism comprises at least one of deep vein thrombosis and pulmonary embolism.

17. The compound or composition according to claim 16, wherein the at least one of deep vein thrombosis and pulmonary embolism occurs following a medical procedure.

18. The compound or composition according to claim 13, wherein said thrombotic disorder comprises dysfunctional coagulation or disseminated intravascular coagulation.

19. The compound or composition according to claim 18, wherein the subject is undergoing percutaneous coronary intervention (PCI).

20. The compound or composition according to claim 13, wherein said disease or disorder comprising a blood clot thrombus further comprises at least one of stroke and one or more transient ischemic attacks (TIA).

21. The compound or composition according to claim 20, wherein said disease or disorder comprising a blood clot thrombus further comprises stroke and wherein the subject has non-valvular atrial fibrillation.

22. The compound or composition according to claim 13, wherein said thrombotic disease or disorder comprising a blood clot thrombus further comprises pulmonary hypertension.

23. The compound or composition according to claim 22, wherein the pulmonary hypertension is caused by at least one of left heart disorder and chronic thromboembolic disease.

24. The compound or composition according to claim 23, wherein the pulmonary hypertension is associated with at least one lung disease.

25. The compound according to any one of claims 1 to 11 or the pharmaceutical composition according to claim 12, for use in treatment of at least one disease or disorder selected from the group consisting of fibrosis, Alzheimer's Disease, multiple sclerosis, pain, a cancer and a recurrent cardiac event after myocardial infarction.

26. The compound or composition according to claim 25, wherein said disease or disorder is fibrosis.

27. The compound or composition according to claim 25, wherein said disease or disorder is Alzheimer's Disease.

28. The compound or composition according to claim 25, wherein said disease or disorder is multiple sclerosis.

29. The compound or composition according to claim 25, wherein said disease or disorder is pain.

30. The compound or composition according to claim 25, wherein said disease or disorder is a cancer.

31. The compound or composition according to claim 25, wherein the disease or disorder is a recurrent cardiac event after myocardial infarction.

32. The compound or composition according to claim 15, wherein the venous thromboembolism is associated with at least one of formation of a thrombus within a vein associated with one or more acquired or inherited risk factors and embolism of peripheral veins caused by a detached thrombus.

33. The compound or composition according to claim 32, wherein the one or more risk factors comprise a previous venous thromboembolism.

34. The compound or composition according to claim 15, wherein the cardiogenic thromboembolism is due to formation of a thrombus in the heart associated with at least one of cardiac arrhythmia, a heart valve defect, prosthetic heart valves or heart disease, and embolism of peripheral arteries caused by a detached thrombus.

35. The compound or composition according to claim 34, wherein the detached thrombus is in the brain.

36. The compound or composition according to claim 35, wherein the detached thrombus causes a transient ischemic attack (TIA).

37. The compound or composition according to claim 34, wherein the cardiogenic thromboembolism is due to non-valvular atrial fibrillation.

38. The compound or composition according to claim 14, wherein the thrombosis is arterial thrombosis.

39. The compound or composition according to claim 38, wherein the arterial thrombosis is due to one or more underlying atherosclerotic processes in the arteries.

40. The compound or composition according to claim 39, wherein the one or more underlying atherosclerotic processes in the arteries cause at least one of obstruction or occlusion of an artery, myocardial ischemia, myocardial infarction, obstruction or occlusion of a peripheral artery, and obstruction or occlusion of the artery after a procedure on a blood vessel.

41. The compound or composition according to claim 13, wherein the treatment comprises an adjunct therapy.

42. The compound or composition according to claim 41, wherein the disease or disorder is myocardial infarction, and the adjunct therapy is in conjunction with thrombolytic therapy.

43. The compound or composition according to claim 41, wherein the disease or disorder is at least one of unstable angina pectoris, thrombosis, and heparin-induced thrombocytopenia, and the adjunct therapy is in combination with antiplatelet therapy.

44. The compound or composition according to claim 41, wherein the disease or disorder is non-valvular atrial fibrillation, and the adjunct therapy is in conjunction with other therapies.

45. The compound or composition according to claim 24, wherein the lung disease is at least one of idiopathic pulmonary fibrosis, non-idiopathic pulmonary fibrosis, and hypoxia.

46. The compound according to any one of claims 1 to 11 or the pharmaceutical composition according to claim 12, for use in prevention of at least one of a thrombotic disorder and a disease or disorder comprising a blood clot thrombus.

47. The compound or composition according to claim 46, wherein said thrombotic disorder comprises one or more of acute coronary syndrome, thromboembolism, and thrombosis.

48. The compound or composition according to claim 47, wherein the thromboembolism comprises at least one of venous thromboembolism, arterial thromboembolism, and cardiogenic thromboembolism.

49. The compound or composition according to claim 46, wherein said thrombotic disorder is disseminated intravascular coagulation.

50. The compound or composition according to claim 46, wherein said disease or disorder comprising a blood clot thrombus further comprises at least one of stroke and one or more transient ischemic attacks (TIA).

51. The compound or composition according to claim 50, wherein said disease or disorder comprising a blood clot thrombus further comprises stroke and wherein the subject has non-valvular atrial fibrillation.

52. The compound or composition according to claim 46, wherein said disease or disorder comprising a blood clot thrombus further comprises pulmonary hypertension.

53. The compound or composition according to claim 52, wherein the pulmonary hypertension is caused by at least one of left heart disorder and chronic thromboembolic disease.

54. The compound or composition according to claim 52, wherein the pulmonary hypertension is associated with at least one lung disease.